ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
A sulfonamide derivative prevents the infamous tumor suppressor p53 from parking at the mitochondria. This activity could mitigate severe side effects of radiation therapy. p53 is best known for triggering cell suicide by binding directly to DNA. The protein is often inactivated in tumor cells, allowing them to grow uncontrollably. But p53 has many cellular roles, including the ability to initiate cell death by binding to mitochondria and unplugging the organelle's pores. This second kiss of death is activated in healthy blood progenitor cells during γ-radiation therapy, leading to nasty side effects. Inhibiting p53's translocation to the mitochondria with pifithrin-µ (shown) controls p53's bad behavior during γ-radiation without compromising its other essential roles in the cell (Nat. Chem. Bio., DOI:10.1038/nchembio809). "Pifithrin-µ allows pharmacological dissection of one of the major branches of p53 function," says author Andrei V. Gudkov from the Lerner Research Institute, in Cleveland. "There's also great therapeutic potential for this small molecule," comments Alexander I. Zaika of Vanderbilt University Medical Center.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X